In vivo, blocking VAP-1 function with an anti-mouse anti-VAP-1 antibody significantly alleviates inflammation in mouse models of arthritis and liver fibrosis.13 BTT1023 appears to be safe and well tolerated in humans: BTT1023 has been given in doses up to 8 mg/kg in patients with rheumatoid arthritis and psoriasis after oral premedication (cetirizine and ibuprofen) and also appears safe and well tolerated in repeated intravenous dosing.14 No cytokine release syndrome was seen. This evidence concerns the gene AOC3 and arthritic joint disease.